Review articles

  1. Cohen, L., Assaraf, Y.G. and Livney, Y.D. (2021) Targeted nanomedicine modalities for prostate cancer treatment. Drug Resist Updat. 56:100762.
  2. Wiesel-Motiuk, N. and Assaraf, Y.G. (2020) The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology. Drug Resist Updat. 53: 100729. PubMed
  3. Golan, Y. and Assaraf, Y.G. (2020) Genetic and Physiological Factors Affecting Human Milk Production and Composition. Nutrients. 12(5):E1500. PubMed
  4. Assaraf, Y.G., Brozovic, A., Gonçalves, A.C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A.B., Xavier, C.P.R. and Vasconcelos, M.H. (2019) The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Updat. 46: 100645. PubMed
  5. Golan, Y., Kambe, T. and Assaraf, Y.G. (2017) The role of the zinc transporter SLC30A2/ZnT2 in transient neonatal zinc deficiency. Metallomics. 9(10):1352-1366. PubMed
  6. Raz, S., Stark, M. and Assaraf, Y.G. (2016) Folylpoly-γ-glutamate synthetase: A key determinant of folate homeostasis and antifolate resistance in cancer. Drug Resist Updat. 28: 43–64. PubMed
  7. Zhitomirsky, B. and Assaraf, Y.G. (2016) Lysosomes as mediators of drug resistance in cancer. Drug Resist Updat. 24:23-33. PubMed
  8. Taylor, S., Spugnini, E.P., Assaraf, Y.G. et. al. (2015) Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resist Updat. [Epub ahead of print]. PubMed
  9. Niewerth, D., Jansen, G., Assaraf, Y.G. et. al. (2015) Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat. 18:18-35. PubMed
  10. Wojtuszkiewicz, A., Assaraf, Y.G., Maas, M.J., Kasper,s G.J., Janse,n G. and Cloos, J. (2014) Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance. Expert Opin Drug Metab Toxicol. 13:1-17. PubMed
  11. Assaraf, Y.G., Leamon, C.P. and Reddy, J.A. (2014) The folate receptor as a rational therapeutic target for personalized cancer treatment.Drug Resist Updat. 17(4-6):89-95. PubMed
  12. Livney, Y.D. and Assaraf, Y.G. (2013) Rationally designed nanovehicles to overcome cancer chemoresistance. Adv Drug Deliv Rev. 65(13-14):1716-30. PubMed
  13. Gonen, N. and Assaraf, Y.G. (2012) Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 15(4):183-210. PubMed
  14. Porcelli, L., Assaraf, Y.G., Azzariti, A., Paradiso, A., Jansen, G. and Peters, G.J. (2011) The impact of folate status on the efficacy of colorectal cancer treatment. Curr Drug Metab. 12(10):975-84. PubMed
  15. Shapira, A., Livney, Y.D., Broxterman, H.J. and Assaraf, Y.G. (2011) Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat. 14(3):150-63. PubMed
  16. Ifergan, I. and Assaraf, Y.G. (2008) Molecular mechanisms of adaptation to folate deficiency. Vitamins and Hormones. 79: 99-143. PubMed
  17. Assaraf, Y.G. (2007) Molecular basis of antifolate resistance. Cancer Metastasis Rev. 26: 153-181. PubMed
  18. Assaraf, Y.G. (2006) The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat. 9: 227-246. PubMed